Polypeptide applicable to administration through vein, abdominal cavity or nasal cavity

An abdominal and venous technology, applied in the field of polypeptide drugs, can solve the problems that the analgesic effect and shelf life cannot reach clinical application, cannot carry out good quality control, cannot carry out large-scale promotion, etc., and achieve long-term drug effects , Excellent analgesic effect and low clinical risk

Active Publication Date: 2019-01-25
SHENZHEN RUIJIAN BIOSCI TECH LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there are technical methods in the prior art to use cell-penetrating peptides to assist conotoxins to cross the blood-brain barrier. For example, ziconotide is packaged in virus particles, and TAT polypeptide is linked to the surface of virus particles. The virus particles Ziconotide can be delivered through the blood-brain barrier. However, the preparation process of this method is complicated, and the virus packaging process cannot perform good quality control, and it is difficult to apply it on a large scale in the industry.
As another example, the N-terminus of the TAT peptide and conotoxin is used as a linking unit to prepare a fusion polypeptide. The fusion polypeptide can pass through the blood-brain barrier and is suitable for intravenous injection. However, the fusion polypeptide connected to the N-terminal Through intravenous injection, the analgesic effect and existence time in the body cannot meet the requirements of clinical application, and large-scale promotion cannot be carried out.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide applicable to administration through vein, abdominal cavity or nasal cavity
  • Polypeptide applicable to administration through vein, abdominal cavity or nasal cavity
  • Polypeptide applicable to administration through vein, abdominal cavity or nasal cavity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] The preparation of embodiment 1 different types of ziconotide fusion peptides

[0043] Four different types of fusion peptides were prepared and named as protected polypeptides MVIIA-a, MVIIA-b, MVIIA-c, and MVIIA-d, respectively. At the same time, ziconotide was prepared and named MVIIA as a control. In this experiment, the F-moc automatic solid-phase synthesis method was adopted, and the specific steps are as follows:

[0044] Synthesis of polypeptides: Protected polypeptides and their derivatives were assembled on resin using a model of the 433A automatic synthesizer (ABI, Foster City, CA). The peptide resin was incubated in suspension for 2.5 hours at room temperature to deprotect the group. The suspension system is composed of 10 ml of TFA, 0.75 g of phenol, 0.25 ml of 1,2-ethanedithiol, 0.5 ml of sulfide anisole and 0.5 ml of water. (Wat methoxycarbonyl (Fmoc), a common alkoxycarbonyl amino protecting group). The resin was separated from the peptide deprotecte...

Embodiment 2

[0047] Example 2: Chemical properties and structural characterization of different types of ziconotide fusion peptides

[0048] 1. Chemical properties of MVIIA and its variants

[0049] The buffer-treated linear peptides were treated for 24-48 hours at 4°C, and then analyzed by high-performance liquid chromatography. It was found that the folding of the linear peptides resulted in the appearance of a major peak and several minor peaks. The buffer system includes 1mM glutathione, 0.1mM oxidized glutathione, 1mM EDTA, and 0.2mg / mL linear peptide, and the pH of the solution is 7.9. The major product was purified and evaluated by analytical reversed-phase high-performance liquid chromatography, and the purity of the peptide was determined to be greater than 98%. Determination was performed with an Ultraflex III TOF / TOF mass spectrometer (Bruker). The prepared polypeptide sequence is shown in Table 1, and its one-step oxidative folding HPLC analysis profile is shown in figure 1 ...

Embodiment 3

[0058] Embodiment 3: Electrophysiological experiments of different types of ziconotide fusion peptides

[0059] In order to further study the electrophysiological effects of different types of improved ziconotide and the inhibitory effect on calcium ion (CaV2.2) channels, the following experiments were carried out:

[0060] HEK293T cells (capable of expressing SV40 large T antigen) were cultured in DMEM high-glucose medium (Gibco) containing 10% fetal bovine serum, 1% penicillin and streptomycin. The incubator environment is 37°C, 5% CO 2 . Dr. Diane Lipscombe provided the alpha of the rat CaV2.2 channel 1B Splice variant e37a, auxiliary subunit α 2 δ 1 and beta 3 Plasmids (Addgene plasmid #26569, #26575, #26574). Then three kinds of plasmids (3μg), 0.4μg enhanced green fluorescent protein gene and liposome were transiently transfected into HEK293T cells. 24 hours after transfection, the cells were seeded on glass slides and incubated in an incubator (37°C, 5% CO 2 ) f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses polypeptide applicable to administration through vein, abdominal cavity or nasal cavity. According to the polypeptide disclosed by the invention, the terminal C of ziconotide is connected with the terminal N of cell penetrating peptide through 3 glycines to obtain polypeptide capable of passing through the blood brain barrier. The polypeptide disclosed by the invention is suitable for the administration through vein, abdominal cavity or nasal cavity while the operation is convenient and the clinical risk is low; when being applied through the vein, abdominal cavity or nasal cavity, the polypeptide has the advantages of long acting time in vivo, good analgesic effect and few peptide side effects and thus is suitable for large-scale clinical application. The polypeptide provided by the invention is easy to prepare, the preparation technology and the preparation process are controllable in quality, and the polypeptide is suitable for large-scale industrial production.

Description

technical field [0001] The invention belongs to the technical field of polypeptide drugs, in particular to a fusion polypeptide of ziconotide. Background technique [0002] Ziconotide (trade name PrialtTM, Elan Pharmaceuticals) is the first conotoxin drug approved by the US Food and Drug Administration (FDA) in 2004. Its target action site is N-type voltage-gated calcium ion channel, and it is the first-line drug for subarachnoid space (intrathecal) compound analgesia. Ziconotide is the artificial synthesis of the hydrophilic polypeptide ω-MVIIA in the venom peptide of the Pacific fish-eating snail—the conch snail—and it is the first new type of non-morphine analgesic used in clinical practice. Its molecular formula is C 102 h 172 N 36 o 32 S 7 , the structural formula: [0003] H-Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys- Cys-NH 2 . [0004] Ziconotide can be used clinically to treat postherpetic neuralgia, phan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K19/00A61K38/17A61K47/42A61P29/00
CPCA61K38/00A61P29/00C07K14/43504C07K2319/10
Inventor 李书鹏张强
Owner SHENZHEN RUIJIAN BIOSCI TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap